Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Rhythm Pharmaceuticals (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025 at 8:00 a.m. ET.
The company will host a live conference call and webcast to present the financial results and provide a corporate update. Participants are encouraged to join ten minutes before the scheduled start time. The webcast will be accessible through the Investor Relations section of Rhythm's website and will remain available for at least 30 days after the call.
Rhythm Pharmaceuticals (Nasdaq: RYTM), un'azienda biofarmaceutica globale in fase commerciale specializzata in malattie neuroendocrine rare, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per mercoledì 7 maggio 2025 alle 8:00 ET.
L'azienda terrà una conferenza telefonica e una webcast in diretta per presentare i risultati finanziari e fornire un aggiornamento aziendale. Si consiglia ai partecipanti di collegarsi dieci minuti prima dell'orario previsto. La webcast sarà accessibile attraverso la sezione Investor Relations del sito web di Rhythm e resterà disponibile per almeno 30 giorni dopo la chiamata.
Rhythm Pharmaceuticals (Nasdaq: RYTM), una compañía biofarmacéutica global en etapa comercial especializada en enfermedades neuroendocrinas raras, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el miércoles 7 de mayo de 2025 a las 8:00 a.m. ET.
La empresa realizará una llamada en conferencia en vivo y una transmisión web para presentar los resultados financieros y proporcionar una actualización corporativa. Se recomienda a los participantes unirse diez minutos antes de la hora programada. La transmisión estará disponible a través de la sección de Relaciones con Inversionistas del sitio web de Rhythm y permanecerá accesible por al menos 30 días después de la llamada.
Rhythm Pharmaceuticals (나스닥: RYTM)는 희귀 신경내분비 질환을 전문으로 하는 글로벌 상업 단계 바이오제약 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 7일 수요일 오전 8시(동부시간)에 예정하고 있습니다.
회사는 재무 결과를 발표하고 기업 현황을 업데이트하기 위해 라이브 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 참가자들은 예정 시작 시간 10분 전에 접속할 것을 권장합니다. 웹캐스트는 Rhythm 웹사이트의 투자자 관계 섹션을 통해 접속할 수 있으며, 콜 종료 후 최소 30일간 제공됩니다.
Rhythm Pharmaceuticals (Nasdaq : RYTM), une entreprise biopharmaceutique mondiale en phase commerciale spécialisée dans les maladies neuroendocrines rares, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mercredi 7 mai 2025 à 8h00 ET.
L'entreprise organisera une conférence téléphonique en direct et une webdiffusion pour présenter les résultats financiers et fournir une mise à jour d'entreprise. Les participants sont invités à se connecter dix minutes avant l'heure prévue. La webdiffusion sera accessible via la section Relations Investisseurs du site web de Rhythm et restera disponible pendant au moins 30 jours après l'appel.
Rhythm Pharmaceuticals (Nasdaq: RYTM), ein globales biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene neuroendokrine Erkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 7. Mai 2025 um 8:00 Uhr ET geplant.
Das Unternehmen wird eine Live-Konferenzschaltung und einen Webcast veranstalten, um die Finanzergebnisse vorzustellen und ein Unternehmensupdate zu geben. Die Teilnehmer werden gebeten, sich zehn Minuten vor Beginn einzuwählen. Der Webcast ist über den Bereich Investor Relations auf der Rhythm-Website zugänglich und bleibt mindestens 30 Tage nach dem Anruf verfügbar.
- None.
- None.
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update.
To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.
A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for at least 30 days following the call.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Setmelanotide Indication
In the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
- Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
- Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.
Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥
USE IN SPECIFIC POPULATIONS
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the release of our financial results and our participation in upcoming events and presentations, including the timing of any of the foregoing. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties and other important factors, including those discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com
FAQ
When will Rhythm Pharmaceuticals (RYTM) release Q1 2025 earnings?
How can investors access RYTM's Q1 2025 earnings call?
How long will RYTM's Q1 2025 earnings webcast be available?
What is Rhythm Pharmaceuticals' main business focus?
